Emerging treatments for pulmonary arterial hypertension

Bibliography

• D’ALONZO GE, BARST RJ, AYRES SM et al.: Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann. Intern. Med. (1991) 115(5):343-349.
   PubMed Web of Science ®Google Scholar
• BARST RJ, RUBIN LJ, LONG WA et al.: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N. Engl. J. Med. (1996) 334(5):296-302.
   PubMed Web of Science ®Google Scholar
• BADESCH DB, TAPSON VF, MCGOON MD et al.: Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann. Intern. Med. (2000) 132(6):425-434.
   PubMed Web of Science ®Google Scholar
• BADESCH DB, ABMAN SH, AHEARN GS et al.: Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest (2004) 126(Suppl. 1):45S.
   Google Scholar
• YANAGISAWA M, KURIHARA H, KIMURA S et al.: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature (1988) 332:411-415.
   PubMed Web of Science ®Google Scholar
• GALIE N, GRIGIONI F, BACCHI-REGGIANI L et al.: Relation of endothelin-1 to survival in patients with primary pulmonary hypertension. Eur. J. Clin. Invest. (1996) 26:273.
   Web of Science ®Google Scholar
• YAMANE K: Endothelin and collagen vascular disease: a review with special reference to Raynaud’s phenomenon and systemic sclerosis. Intern. Med. (1994) 33(10):579-582.
   PubMed Web of Science ®Google Scholar
• GIAID A, YANAGISAWA M, LANGLEBEN D et al.: Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. (1993) 328:1732-1739.
   PubMed Web of Science ®Google Scholar
• OHLSTEIN EH, DOUGLAS SA: Endothelin-1 modulates vascular smooth muscle structure and vasomotion: implications in cardiovascular pathology. Drug Dev. Res. (1993) 29:108-128.
   Web of Science ®Google Scholar
• FUKURODA T, FUJIKAWA T, OZAKI S et al.: Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem. Biophys. Res. Commun. (1994) 199:1461-1465.
   PubMed Web of Science ®Google Scholar
• OZAKI S, OHWAKI K, IHARA M et al.: ETB-mediated regulation of extracellular levels of endothelin-1 in cultured endothelial cells. Biochem. Biophys. Res. Commun. (1995) 209:483-489.
   PubMed Web of Science ®Google Scholar
• CHANNICK RN, SIMONNEAU G, SITBON O et al.: Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet (2001) 358:1119-1123.
   PubMed Web of Science ®Google Scholar
• RUBIN LJ, BADESCH DB, BARST RJ et al.: Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. (2002) 346:896-903.
   PubMed Web of Science ®Google Scholar
• BARST RJ, LANGLEBEN D, BADESCH D et al.; STRIDE-2 STUDY GROUP: Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J. Am. Coll. Cardiol. (2006) 47(10):2049-2056.
   PubMed Web of Science ®Google Scholar
• BARST RJ, LANGLEBEN D, FROST A et al.; for the STRIDE-1 STUDY GROUP: sitaxsentan therapy for pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. (2004) 169:441-447.
   PubMed Web of Science ®Google Scholar
• GALIE N, BADESCH D, OUDIZ R et al.: Ambrisentan therapy for pulmonary arterial hypertension. J. Am. Coll. Cardiol. (2005) 46:529-535.
   PubMed Web of Science ®Google Scholar
• SIMONNEAU G, BARST RJ, GALIE N et al.; TREPROSTINIL STUDY GROUP: Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med. (2002) 165(6):800-804.
   PubMed Web of Science ®Google Scholar
• GAINE SP, BARST RJ, RICH S et al.: Acute hemodynamic effects of subcutaneous UT-15 in primary pulmonary hypertension. Am. J. Respir. Crit. Care Med. (1999) 159:A161.
   Google Scholar
• BARST RJ, SIMONNEAU G, RICH S et al.; for the UNIPROST PAH STUDY GROUP: Efficacy and safety of chronic subcutaneous infusion of UT-15 (Uniprost) in pulmonary arterial hypertension (PAH). Circulation (2000) 102:100-101.
   Google Scholar
• BARST RJ, HORN EM, WIDLITZ AC, GOUDIE et al.: Efficacy of long-term subcutaneous infusion of UT-15 in primary pulmonary hypertension. Eur. Heart J. (2000) 21:315.
   PubMedGoogle Scholar
• TAPSON VF, GOMBERG-MAITLAND M, MCLAUGHLINVV et al.: Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter open-label, 12-week trial. Chest (2006) 129(3):683-688.
   PubMed Web of Science ®Google Scholar
• OKANO Y, YOSHIOKA T, SHIMOUCHI A et al.: Orally active prostacyclin analogue in primary pulmonary. Lancet (1997) 349:1365.
   PubMed Web of Science ®Google Scholar
• GALIE N, MANES A, BRANZI A: The new clinical trials on pharmacological treatment in pulmonary arterial hypertension. Eur. Respir. J. (2002) 20:1037-1049.
   PubMed Web of Science ®Google Scholar
• BARST RJ, MCGOON M, MCLAUGHLIN V et al.; for the BERAPROST STUDY GROUP: Beraprost therapy for pulmonary arterial hypertension. J. Am. Coll. Cardiol. (2003) 41:2119-2125.
   PubMed Web of Science ®Google Scholar
• KAUKINEN S, YLITALO P, PESSI T, VAPAATALO H: Hemodynamic effects of iloprost, a prostacyclin analogue. Clin. Pharmacol. Ther. (1984) 36:464-469.
   PubMed Web of Science ®Google Scholar
• SKUBALLA W, RADUCHEL B, VORBRUGGEN H: Chemistry of stable prostacyclin analogues; synthesis of iloprost. In: Prostacyclin and its stable analogue Iloprost. Gryglewski RS, Stock G (Eds), Springer, Berlin, Heidelberg, Germany (1987):17-24.
   Google Scholar
• HOEPER MM, SCHWARZE M, EHLERDING S et al.: Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N. Engl. J. Med. (2000) 342:1866-1870.
   PubMed Web of Science ®Google Scholar
• WENSEL R, OPITZ CF, EWER R et al.: Effects of iloprost inhalation on exercise capacity and ventilatory efficiency in patients with primary pulmonary hypertension. Circulation (2000) 101:2388-2392.
   PubMed Web of Science ®Google Scholar
• OLSCHEWSKI H, SIMONNEAU G, GALIE N et al.: Inhaled iloprost for severe pulmonary hypertension. N. Engl. J. Med. (2002) 347:322-329.
   PubMed Web of Science ®Google Scholar
• VOSWINCKEL R, GHOFRANI HA, GRIMMINGER F, SEEGER W, OLSCHEWSKI H: Inhaled treprostinil for treatment of chronic pulmonary arterial hypertension. Ann. Intern. Med. (2006) 144:149-150.
   PubMed Web of Science ®Google Scholar
• PALMER RM, FERRIGE AG, MONCADA S: Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature (1987) 327(6122):524-526.
   PubMed Web of Science ®Google Scholar
• BEAVO JA, REIFSNYDER DH: Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol. Sci. (1990) 11(4):150-155.
   PubMed Web of Science ®Google Scholar
• HANSON KA, ZIEGLER JW, RYBALKIN SD, MILLER JW, ABMAN SH, CLARKE WR: Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity. Am. J. Physiol. (1998) 275(5 Pt 1):L931-L941.
   PubMed Web of Science ®Google Scholar
• GALIE N, GHOFRANI H, TORBICKI A et al.: Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med. (2005) 353:2148-2157.
   PubMed Web of Science ®Google Scholar
• WAGENVOORT CA, WAGENVOORT N: Primary pulmonary hypertension. Wiley & Sons, New York, USA (1977).
   Google Scholar
• BARST RJ: Medical therapy of pulmonary hypertension: an overview of treatment and goals. In: Clinics in Chest Medicine. Rich S, McLaughlin VV (Eds), WB Saunders, Philadelphia, USA (2001) 22:509-515.
   Google Scholar
• HUMBERT M, SITBON O, SIMONNEAU G: Treatment of pulmonary arterial hypertension. N. Engl. J. Med. (2004) 351(14):1425-1436.
   PubMed Web of Science ®Google Scholar
• GIAID A, SALEH D: Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. (1995) 333(4):214-221.
   PubMed Web of Science ®Google Scholar
• DENG Z, MORSE JH, SINGER SL et al.: Familial primary pulmonary hypertension (gene PPH 1) is caused by mutations in the bone morphogenetic protein-receptor-II gene. Am. J. Hum. Genet. (2000) 67:737-744.
   PubMed Web of Science ®Google Scholar
• LANE KB, MACHADO RD, PAUCIULO MW et al.: Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, causes familial primary pulmonary hypertension. Nat. Genet. (2000) 26(1):81-84.
   PubMed Web of Science ®Google Scholar
• CHRISTMAN BW, MC PHERSON CD, NEWMAN JH et al.: An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N. Engl. J. Med. (1992) 327:70-75.
   PubMed Web of Science ®Google Scholar
• STEWART DJ, LEVY RD, CERNACEK P et al.: Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann. Intern. Med. (1991) 114:467-469.
   Google Scholar
• WAGENVOORT CA, WAGENVOORT N: Pathology of the Eisenmenger syndrome and primary pulmonary hypertension. Adv. Cardiol. (1974) 11:123-130.
   PubMedGoogle Scholar
• SHUTTLEWORTH TJ, THORNDYKE MC: An endogenous peptide stimulates secretory activity in the elasmobranch rectal gland. Science (1984) 225:319-321.
   PubMed Web of Science ®Google Scholar
• NELLGARD P, BOJO L, CASSUTO J: Importance of vasoactive intestinal peptide and somatostatin for fluid losses in small-bowel obstruction. Scand. J. Gastroenterol. (1995) 30:464-469.
   PubMed Web of Science ®Google Scholar
• PETKOV V, MOSGOELLER W, ZIESCHE R et al.: Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J. Clin. Invest. (2003) 111:1339-1346.
   PubMed Web of Science ®Google Scholar
• USDIN TB, BONNER TI, MEZEY E: Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology (1994) 135:2662-2680.
   PubMed Web of Science ®Google Scholar
• BUSTO R, PRIETO JC, BODEGA G, ZAPATERO J, CARRERO I: Immunohistochemical localization and distribution of VIP/PACAP receptors in human lung. Peptides (2000) 21:265-269.
   PubMed Web of Science ®Google Scholar
• GUNAYDIN S, IMAI Y, TAKANASHI Y et al.: The effects of vasoactive intestinal peptide on monocrotaline induced pulmonary hypertensive rabbits following cardiopulmonary bypass: a comparative study with isoproterenol and nitroglycerine. Cardiovasc. Surg. (2002) 10:138-145.
   PubMedGoogle Scholar
• RUBENSTEIN I: Human VIP-alpha: an emerging biologic response modifier to treat primary pulmonary hypertension. Expert Rev. Cardiovasc. Ther. (2005) 3(4):565-569.
   PubMedGoogle Scholar
• JANKOV RP, KANTORES C, BELCASTRO R et al.: A role for platelet-derived growth factor beta-receptor in a newborn rat model of endothelin-mediated pulmonary vascular remodeling. Am. J. Physiol. Lung Cell Mol. Physiol. (2005) 288(6):L1162-L1170.
   PubMed Web of Science ®Google Scholar
• SCHERMULY RT, DONY E, GHOFRANI HA et al.: Reversal of experimental pulmonary hypertension by PDGF inhibition. J. Clin. Invest. (2005) 115:2811-2821.
   PubMed Web of Science ®Google Scholar
• BARST RJ: PDGF Signaling in pulmonary arterial hypertension. J. Clin. Invest. (2005) 115:2691-2694.
   PubMed Web of Science ®Google Scholar
• GHOFRANI HS, SEEGER WA, GRIMMINGER F: Imatinib for the treatment of pulmonary arterial hypertension. N. Engl. J. Med. (2005) 353:1412-1413.
   PubMed Web of Science ®Google Scholar
• PATTERSON KC WEISSMAN A, AHMADI T, FARBER HW: Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann. Intern. Med. (2006) 145:152-153.
   PubMed Web of Science ®Google Scholar
• KAIBUCHI K, KURODA S, AMANO M: Regulation of the cytoskeleton and cell adhesion by the Rho family GTPases in mammalian cells. Ann. Rev. Biochem. (1999) 68:459-486.
   PubMed Web of Science ®Google Scholar
• KIMURA K, ITO M, AMANO M et al.: Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science (1996) 273(5272):245-248.
   PubMed Web of Science ®Google Scholar
• SOMLYO AP, SOMLYO AV: Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol. Rev. (2003) 83(4):1325-1358.
   PubMed Web of Science ®Google Scholar
• ITO M, NAKANO T, ERDODI F, HARTSHORNE DJ: Myosin phosphatase: structure, regulation and function. Mol. Cell. Biochem. (2004) 259(1-2):197-209.
   PubMed Web of Science ®Google Scholar
• UEHATA M, ISHIZAKI T, SATOH H et al.: Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature (1997) 389(6654):990-994.
   PubMed Web of Science ®Google Scholar
• FAGAN KA, OKA M, BAUER NR et al.: Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. Am. J. Physiol. Lung Cell Mol. Physiol. (2004) 287(4):L656-L664.
   PubMed Web of Science ®Google Scholar
• NAGAOKA T, MORIO Y, CASANOVA N et al.: Rho/Rho kinase signaling mediates increased basal pulmonary vascular tone in chronically hypoxic rats. Am. J. Physiol. Lung Cell Mol. Physiol. (2004) 287(4):L665-L672.
   PubMed Web of Science ®Google Scholar
• ABE K, SHIMOKAWA H, MORIKAWA K et al.: Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ. Res. (2004) 94(3):385-393.
   PubMed Web of Science ®Google Scholar
• NAGUMO H, SASAKI Y, ONO Y, OKAMOTO H, SETO M, TAKUWA Y: Rho kinase inhibitor HA-1077 prevents Rho-mediated myosin phosphatase inhibition in smooth muscle cells. Am. J. Physiol. Cell Physiol. (2000) 278(1):C57-C65.
   PubMed Web of Science ®Google Scholar
• FUKUMOTO Y, MATOBA T, ITO A et al.: Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart (2005) 91(3):391-392.
   PubMed Web of Science ®Google Scholar
• NAGAOKA T, FAGAN KA, GEBB SA et al.: Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Am. J. Respir. Crit. Care Med. (2005) 171(5):494-499.
   PubMed Web of Science ®Google Scholar
• MARTIN KB, KLINGER JR, ROUNDS SI: Pulmonary arterial hypertension: new insights and new hope. Respirology (2006) 11(1):6-17.
   PubMed Web of Science ®Google Scholar
• KAWUT SM, HORN EM, BEREKASHVILI KK et al.: Selective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertension. Pulm. Pharmacol. Ther. (2006) 19(5):370-374.
   PubMed Web of Science ®Google Scholar
• GHOFRANI HA, ROSE F, SCHERMULY RT et al.: Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J. Am. Coll. Cardiol. (2003) 42(1):158-164.
   PubMed Web of Science ®Google Scholar